St Jude Medical (NYSE: STJ) and Uroplasty (NASDAQ:UPI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.
Valuation and Earnings
This table compares St Jude Medical and Uroplasty’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|St Jude Medical||N/A||N/A||N/A||$2.28||N/A|
St Jude Medical pays an annual dividend of $1.24 per share. Uroplasty does not pay a dividend. St Jude Medical pays out 54.4% of its earnings in the form of a dividend. Uroplasty has increased its dividend for 6 consecutive years.
Institutional and Insider Ownership
82.7% of St Jude Medical shares are held by institutional investors. 4.8% of St Jude Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares St Jude Medical and Uroplasty’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|St Jude Medical||14.14%||19.40%||6.75%|
This is a breakdown of current ratings and target prices for St Jude Medical and Uroplasty, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|St Jude Medical||0||0||0||0||N/A|
St Jude Medical beats Uroplasty on 6 of the 8 factors compared between the two stocks.
St Jude Medical Company Profile
St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company’s product categories include tachycardia implantable cardioverter defibrillator systems; atrial fibrillation products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products, and Thoratec products.
Uroplasty Company Profile
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for St Jude Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for St Jude Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.